Contributions Made by CDC25 Phosphatases to Proliferation of Intestinal Epithelial Stem and Progenitor Cells by Lee, Gwanghee et al.
Contributions Made by CDC25 Phosphatases to
Proliferation of Intestinal Epithelial Stem and Progenitor
Cells
Gwanghee Lee
1¤, Sofia Origanti
1,2,6, Lynn S. White
1,2,6, Jinwu Sun
1,3, Thaddeus S. Stappenbeck
4, Helen
Piwnica-Worms
1,2,5,6*
1Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2BRIGHT Institute, Washington
University School of Medicine, St. Louis, Missouri, United States of America, 3Molecular Imaging Center, Washington University School of Medicine, St. Louis, Missouri,
United States of America, 4Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America,
5Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 6Howard Hughes Medical Institute, Chevy
Chase, Maryland, United States of America
Abstract
The CDC25 protein phosphatases drive cell cycle advancement by activating cyclin-dependent protein kinases (CDKs).
Humans and mice encode three family members denoted CDC25A, -B and -C and genes encoding these family members
can be disrupted individually with minimal phenotypic consequences in adult mice. However, adult mice globally deleted
for all three phosphatases die within one week after Cdc25 disruption. A severe loss of absorptive villi due to a failure of
crypt epithelial cells to proliferate was observed in the small intestines of these mice. Because the Cdc25s were globally
deleted, the small intestinal phenotype and loss of animal viability could not be solely attributed to an intrinsic defect in the
inability of small intestinal stem and progenitor cells to divide. Here, we report the consequences of deleting different
combinations of Cdc25s specifically in intestinal epithelial cells. The phenotypes arising in these mice were then compared
with those arising in mice globally deleted for the Cdc25s and in mice treated with irinotecan, a chemotherapeutic agent
commonly used to treat colorectal cancer. We report that the phenotypes arising in mice globally deleted for the Cdc25s are
due to the failure of small intestinal stem and progenitor cells to proliferate and that blocking cell division by inhibiting the
cell cycle engine (through Cdc25 loss) versus by inducing DNA damage (via irinotecan) provokes a markedly different
response of small intestinal epithelial cells. Finally, we demonstrate that CDC25A and CDC25B but not CDC25C compensate
for each other to maintain the proliferative capacity of intestinal epithelial stem and progenitor cells.
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Introduction
The CDC25 phosphatases are critical components of the cell
cycle engine that function to drive cell cycle transitions by
dephosphorylating the CDKs [1–6]. We recently described a
genetic model that enables the cell division cycle to be acutely
halted in adult mice [7]. This was accomplished by the targeted
disruption of genes encoding the CDC25 family of protein
phosphatases. In this model, adult mice lacking two members of
the CDC25 family (CDC25B and CDC25C) were globally deleted
for the third family member (CDC25A) using transgenic mice
expressing a tamoxifen-driven Cre recombinase from the ubiqui-
tously expressed Rosa26 (R26) locus [8]. Despite the fact that the
CDC25s were deleted in all tissues of these triple knockout (TKO)
mice, the major phenotype observed is in the small intestine where
a loss of epithelial cell proliferation was accompanied by a
corresponding loss of absorptive villi and animals died within a
week after Cdc25A disruption. Despite the inhibition of cell
division, overall crypt architecture was maintained and strikingly,
neither apoptosis nor inflammation were observed to any
significant level in the small intestines of these animals.
Given that the epithelium of the adult mammalian small
intestine is in constant dialog with its underlying mesenchyme to
direct progenitor proliferation, lineage commitment, terminal
differentiation and ultimately cell death and given that Cre
expression and therefore Cdc25A deletion occurred in cells of the
underlying mesenchyme, the phenotypes observed in the small
intestines of TKO mice could not be solely attributed to an intrinsic
defect in the inability of small intestinal stem and progenitor cells
to divide. For example, loss of CDC25s in neutrophils could have
been responsible for the failure of inflammatory cells to infiltrate
the small intestinal crypts of TKO mice. Therefore, we specifically
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15561deleted the CDC25s in intestinal epithelial cells by way of a
tamoxifen-dependent Cre recombinase expressed from the murine
villin promoter [9]. In addition, we generated mice that can be
conditionally deleted for CDC25B. These mice were used to
address several issues relevant to the CDC25 family of protein
phosphatases and to the homeostasis of the small intestinal stem
cell niche including (1) how the small intestine responds when cell
division is blocked in epithelial cells but not in other cells and
tissues of the small intestine such as mesenchyme, muscle, blood
and endothelium; (2) how the small intestine responds to loss of
Figure 1. Targeted disruption of Cdc25B in mice. (A) Structure of targeting vector and chromosomal organization of Cdc25B locus before and
after Cre-mediated excision. The genomic organization of the mouse Cdc25B gene was disrupted by inserting into intron 1 the neomycin
phosphotransferase cDNA driven by the phosphoglycerine kinase promoter (pGK-neo) as a selectable marker. Exons are represented by black boxes.
The location of Hind III (H), Bam HI (B) and Kpn I (K) site is indicated and loxP sites are represented by yellow triangles. Sizes of upstream (3.3 kb) and
downstream (4.5 kb) homologous arms are indicated. Position of probes used for Southern blotting are shown. Red triangles depict the locations of
PCR primers used for genotyping. Abbreviations: +, wild type allele; R, recombinant allele; F, floxed allele; WT, wild type. (B–C) Southern blot analysis
demonstrating homologous recombination in the Cdc25B locus. ES cell genomic DNA was digested with Hind III (B) and Bam HI (C), and Southern
blotting was performed using the 59 and 39 probes shown in panel A. The genotype of each ES cell line is indicated. The location of size markers is
shown on the left. (D) Southern blot analysis demonstrating Cre-mediated recombination in the Cdc25B locus. ES cell clones containing the
recombinant allele were expanded and transiently transfected with a plasmid encoding Cre recombinase. Genomic DNA was digested with Kpn I (K),
and Southern blotting was performed using the internal probe shown in panel A. The genotype of each ES cell line is indicated. Location of size
markers is shown on left. (E) PCR analysis of mouse tail DNA. Mouse tail DNA was amplified with PCR primers depicted as red triangles in panel A. The
wild type (+) allele produced a 383 bp PCR product and floxed allele (F) produced a 433 bp PCR product. The genotype of each mouse is indicated.
The location of size markers is shown on the right.
doi:10.1371/journal.pone.0015561.g001
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DNA damage (chemotherapy) (3) whether the failure to observe
apoptosis and inflammation in the small intestines of TKO mice
was due to the disruption of CDC25s in cells and tissues other than
intestinal epithelial cells and (4) which of the three CDC25 family
members are required to drive proliferation of intestinal epithelial
stem cells and progenitors.
Results
Disruption of Cdc25A in intestinal epithelial cells of adult
mice
Mice expressing a tamoxifen-dependent Cre recombinase
driven by the murine villin promoter (vil-Cre-ER
T2) [9] were
employed to disrupt Cdc25s specifically in intestinal epithelial cells.
In these mice, administration of tamoxifen induces Cre-recombi-
nase activity exclusively in small and large intestinal epithelial cells
including stem cells. vil-Cre-ER
T2 mice were crossed with mice
containing floxed alleles of Cdc25A [7] to generate mice containing
one floxed and one null allele of Cdc25A (vA
f/2). Additional crosses
were carried out to generate mice containing one null and one
floxed allele of Cdc25A that were also disrupted for Cdc25B
(vA
f/-BKO), Cdc25C (vA
f/-CKO) or both Cdc25B and Cdc25C
(vA
f/-BCKO). In addition, mice containing floxed alleles of Cdc25B
were generated and crossed with vil-Cre-ER
T2 transgenic mice
to fgenerate mice with one null and one floxed allele of
Cdc25B (vB
f/2). The strategy used for generating Cdc25B
conditional mice is shown in Fig. 1. Wild-type and Vil-Cre-ER
T2
mice were used as controls throughout our studies.
vA
f/- mice were bred to a Cre-inducible b-galactosidase reporter
line (R26R) [10] to enable deletion efficiencies at floxed loci to be
readily monitored. X-gal (5-bromo-4-chloro-3-indolyl-b-D-galac-
topyranoside) staining revealed efficient recombination when
tamoxifen was dosed at a concentration of 4 mg per 25 g body
weight for 5 consecutive days (Fig. 2A, B). X-gal staining was
observed exclusively in the epithelium of both the small and large
intestines demonstrating the specificity of the villin promoter for
these tissues (data not shown). The gross and histological
appearance of all organs, with the exception of intestines (see
below), was indistinguishable between tamoxifen-injected
vA
f/-BKO and vA
f/-BCKO and all other mice. The deletion
frequency (conversion of floxed to null allele) was ,40% in the
small and large intestines (Fig. 2C). However, this is likely an
underestimate given the presence of DNA derived from non-
epithelial cell types (muscle, blood and mesenchyme) that do not
express Cre recombinase.
Significant shortening of small intestines in vABKO and
vTKO mice
Mice globally deleted for all three CDC25s exhibit an ,20%
reduction in body weight within one week of the induction of
global Cre expression [7]. This weight loss was also associated with
significant mortality. To determine the consequences of deleting
Cdc25A specifically in intestinal epithelium (in a background of
Figure 2. Specific deletion of Cdc25A in intestinal epithelial cells. (A, B) vR26R;A
f/2 and vA
f/2 mice were injected with tamoxifen for 5
consecutive days and then sacrificed 3 days after the final injection. Frozen sections of small intestines were prepared and stained with X-gal to
visualize Cre-mediated deletion frequencies. Scale bar: 200 mm. (C) Genomic DNA isolated from the small and large intestines of vA
f/2 mice 3 days
after the final tamoxifen-injection was digested with Bst XI followed by Southern blotting. Deletion frequencies are shown below the each lane. (D)
Mice were weighed prior to injection and 3 days after the final tamoxifen injection. Data is presented as mean +/2 standard error of the mean (SEM).
Asterisks indicate significantly different from WT mice injected with tamoxifen as determined by a Student’s t-test. *, P,0.05; **, P,0.01;
***, P,0.001. The actual P-values are 0.86 (vil-Cre-ER
T2), 0.15 (vAKO), 0.87 (vBKO), 0.00007 (vABKO), 0.11(vACKO) and 0.0004 (vTKO).
doi:10.1371/journal.pone.0015561.g002
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mice were compared prior to injection (day 1) and prior to sacrifice
on day 8 (Fig. 2D). A significant decrease in weight (17%) and
increased mortality (5 of 11 vTKO mice died by day 8) were also
observed in these mice. Interestingly, a similar weight loss was
observed when only two family members (Cdc25A and Cdc25B)
were disrupted in intestinal epithelium (vABKO mice) and vABKO
mice also showed increased mortality by day 8 (2 of 5 vABKO mice
died by day 8). In contrast, mice disrupted for Cdc25A alone,
Cdc25B alone, or both Cdc25A and Cdc25C were not significantly
different from control littermates (WT and vil-Cre-ER
T2; Fig. 2D).
These results indicate that small intestinal homeostasis in mice
requires CDC25A or CDC25B but not CDC25C.
A significant shortening of the small intestines was measured in
vABKO (44%) and vTKO (32%) mice relative to WT mice within
one week of the first tamoxifen injection (Fig. 3A). This phenotype
was not a condition existing prior to tamoxifen injection, as small
intestinal lengths of vA
f/2BKO and vA
f/2BCKO mice were not
different from controls (Fig. 3A). In contrast, the length of the
small intestine did not change significantly after tamoxifen
injection of vB
f/2 or vA
f/2CKO animals (Fig. 3A). A mild decrease
(,11%) in small intestinal length was observed in animals
conditionally deleted for Cdc25A (vAKO). As additional controls,
wild type littermates (WT) and vil-Cre-ER
T2 transgenic mice were
also injected with tamoxifen and showed no significant differences
in small intestinal length (Fig. 3A). We noted that the frequency of
Cre-mediated deletion of the floxed Cdc25A allele in the small
intestines of tamoxifen-treated mice was comparable for each
genotype (compare Fig. 2C and Fig. 4). Since the villin promoter
expresses Cre in both small and large intestinal epithelium, we also
measured the lengths of the large intestines of mice before and
after tamoxifen treatment. Lengths of large intestines were
significantly shorter in both vABKO (37% decrease) and vTKO
(27% decrease) mice (Fig. 5). Mice doubly deleted for both Cdc25A
and Cdc25C (vACKO) also showed a modest (15%) but significant (p
= 0.04) reduction in large intestinal length.
Small intestinal phenotypes in tamoxifen-treated mice
Disruption of both Cdc25A and Cdc25B (vABKO) or all three
Cdc25s (vTKO) in intestinal epithelium also caused a significant loss
Figure 3. Loss of homeostasis in small intestines of vABKO and vTKO mice. (A) Mice were injected with tamoxifen for five consecutive days
and then sacrificed 3 days after the final injection. Small intestines were isolated and length determinations were made. Small intestine lengths were
normalized to body weights, which were determined prior to the first tamoxifen-injection. Data is presented as mean +/2 SEM. Asterisk (*) indicates
significantly different after tamoxifen injection as determined by a Student’s t-test. *, P,0.05; **, P,0.01; ***, P,0.001. The actual P-values are 0.38
(WT), 0.76 (vil-Cre-ER
T2), 0.003 (vAKO), 0.31 (vBKO), 0.002 (vABKO), 0.46 (vACKO) and 0.004 (vTKO). The small intestinal lengths of vAKO, vABKO and vTKO
mice were significantly different from WT mice injected with tamoxifen as determined by a Student’s t-test. *, P,0.05; **, P,0.01; ***, P,0.001.
Actual P-values are 0.40 (vil-Cre-ER
T2), 0.03 (vAKO), 0.10 (vBKO), 0.00006 (vABKO), 0.36 (vACKO) and 0.0006 (vTKO). (B) Duodenums isolated from mice
treated as described in A were photographed under a dissection microscope. Scale bar: 0.5 mm. (C) Significant shortening of villi in small intestines of
vABKO and vTKO mice. Length of individual villi shown in panel B were measured (30 villi per mouse). Data is presented as mean +/2 SEM. Asterisk (*)
indicates significantly different after tamoxifen injection as determined by a Student’s t-test. P-values are 0.00008 (vABKO) and 0.007 (vTKO). Villi
lengths of vil-Cre-ER
T2, vABKO and vTKO mice were significantly different from WT mice injected with tamoxifen as determined by a Student’s t-test.
*, P,0.05; **, P,0.01; ***, P,0.001. Actual P-values are 0.001 (vil-Cre-ER
T2), 0.27 (vAKO), 0.45 (vBKO), 0.0005 (vABKO), 0.25 (ACKO) and 0.03 (vTKO).
doi:10.1371/journal.pone.0015561.g003
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corresponding quantification in Fig. 3C). Shortened villus height
was also observed in the jejunums and ileums of these mice (data
not shown). In contrast, disruption of a single Cdc25 family
member or both Cdc25A and Cdc25C in intestinal epithelium did
not affect small intestinal villus height. Taken together, these
results demonstrate that loss of Cdc25C does not contribute to the
phenotypes observed in TKO mice. Furthermore, the decrease in
villus height measured in tamoxifen-treated vA
f/2BCKO mice
(45%) was similar to that observed in mice globally deleted for all
three Cdc25s (47%) [7]. These results argue that the phenotypes
observed in the small intestines of mice globally deleted for all
three Cdc25s is due to defects in intestinal epithelial cells and that
loss of the Cdc25s in neighboring mesenchyme does not contribute
to the observed phenotypes.
Histological examination of small intestines also revealed loss of
epithelial cells within crypts of vABKO and vTKO mice (Fig. 6A).
Cellular composition of crypts was quantified by counting the
number of crypt epithelial cells and Paneth cells (Fig. 6B). The
number of epithelial cells/crypt was greatly diminished in vABKO
(57% decrease) and vTKO (46% decrease) mice. Despite the
reduced cellularity of crypts in these mice, individual epithelial
cells appeared to undergo a process of hypertrophy, thus
accounting for the maintenance of overall crypt structure observed
in vABKO and vTKO mice.
The number of mature Paneth cells/crypt was similar in vABKO
and vTKO mice relative to controls suggesting that loss of CDC25s
impacted replicating progenitors rather than fully differentiated
Paneth cells (Fig. 6B). Indeed, mitotic cells were nearly absent in
vABKO and vTKO mice (Fig. 7C). In addition, BrdU-labeling
experiments revealed a significant decrease of S-phase cells in the
crypts of vABKO and vTKO mice (Fig. 7A). We reported previously
that intestinal epithelial cells arrest in the G1- and G2- phases of
the cell division cycle upon global deletion of the CDC25s (17).
The CDKs are regulated by reversible phosphorylation and
phosphorylation of tyrosine 15 (phospho-Tyr-15) maintains both
CDK1 and CDK2 in an inactive state until this residue is
dephosphorylated by the CDC25s. We predicted that levels of
phospho-Tyr-15 would be elevated in crypt epithelial cells lacking
the CDC25s. As seen in Fig. 7E, levels of phospho-Tyr-15 Cdk1
are greatly elevated in the crypts of vTKO mice compared with WT
mice. This observation is consistent with the loss of S- (Fig. 7A)
and M-phase (Fig. 7C) cells in vTKO mice.
Cell death did not appear to play a role in the crypt epithelial
cell loss of vABKO and vTKO mice as only occasional apoptotic cells
(,1 apoptotic cell per 4 or 5 crypts) were observed in the crypts of
these mice (Fig. 7B and 7D). In contrast, a higher level of apoptosis
(up to 6% of total epithelial cells/crypt) was observed in
tamoxifen-treated vil-Cre-ER
T2, vA
f/2, vB
f/2 and vA
f/2CKO mice.
Apoptosis was not observed in tamoxifen-treated WT mice. These
results indicate that apoptosis is caused by Cre expression in
proliferating epithelium. This conclusion is supported by the
observed low level of apoptosis in small intestinal crypts of vABKO
and vTKO mice where proliferation was halted (Fig. 7A).
Enhanced Wnt signaling and differentiation in intestinal
epithelial cells disrupted for Cdc25 family members
Acute disruption of cell proliferation in small intestinal crypts,
due to global CDC25 loss, leads to enhanced Wnt-signaling and
concomitant differentiation of small intestinal epithelial cell
progenitors along multiple lineages [7]. Thus, the presence of
nuclear beta-catenin was monitored to determine if Wnt signaling
was also enhanced when Cdc25s were specifically disrupted in
intestinal epithelium. As seen in Fig. 8(A, B) significantly more
epithelial cells stained positive for nuclear b-catenin in both vABKO
(middle panel) and vTKO (right panel) mice compared with those
in vil-Cre-ER
T2 (left panel) mice.
Canonical Wnt-signaling has many functions in the small
intestines including maintaining crypt structure [11,12], promot-
ing differentiation of progenitors along the secretory lineage [13–
15] and maintaining the self-renewal capacity of stem cells [16–
18]. Histologic sections of vABKO and vTKO small intestinal crypts
also showed extensive premature differentiation along multiple
epithelial lineages. PAS/alcian blue-stained sections of vABKO and
vTKO small intestines did not reveal Crypt Base Columnar (CBC)
cells. Instead, cells with scattered, small PAS/alcian blue-positive
apical granules were observed, consistent with the conclusion that
CBC cells differentiated along the Paneth cell lineage under these
conditions (Fig. 8C).
Electron microscopic analysis confirmed the effects of epithelial
cell cycle arrest on differentiation (Fig. 9). Both mature and
immature Paneth cells (the latter contains much smaller granules
than mature cells) were present in crypt bases of vABKO (Fig. 9B, C)
Figure 4. Tamoxifen injection induced efficient recombination
within Cdc25A and Cdc25B loci. (A) Genomic DNA isolated from the
small and large intestines of tamoxifen-treated mice were assessed for
Cre-mediated excision by Southern blotting. Deletion frequencies are
shown below each lane and were determined by measuring band
intensities using a Molecular Dynamics Storm imager. (B) Total RNA
isolated from the small intestine (jejunum) of tamoxifen-treated WT and
vB
f/2 mice was reverse-transcribed into cDNA. qRT-PCR was used to
determine relative amounts of Cdc25B mRNA. The data is presented as
mean +/2 SEM. Asterisk (*) indicates significantly different from WT, P
= 0.012 by Student’s t-test. Note that vB
f/2 mice are generated by
crossing Cdc25B null mice [26] with Cdc25B conditional mice. The PCR
primers detect transcript arising from the null allele but not the deleted
floxed allele. Thus, a 50% decrease in relative expression indicates
complete loss of Cdc25B expression.
doi:10.1371/journal.pone.0015561.g004
Disruption of CDC25s in Intestinal Epithelium
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15561and vTKO (Fig. 9D, E). CBC cells were not readily identified in
crypts of these mice and were replaced instead by immature Paneth
cells. These immature Paneth cells were not readily apparent in H&
E stained sections due to the small size of granules (Fig. 6) but were
readilyobserveduponstainingwithPeriodicAcidSchiff/alcianblue
(Fig.8C)orbyEM(Fig.9).Takentogether,theseresults confirmthe
observation that loss of epithelial cell proliferation causes premature
differentiation of CBC cells into Paneth cells.
Response of intestinal epithelial cells to chemotherapy
versus Cdc25 deletion
Blocking CDC25 function directly inhibits cell division by
preventing activation of the cell cycle engine. In contrast, radiation
and chemotherapy, current mainstays of cancer treatment, inhibit
cell division indirectly by inducing DNA damage. Our hypothesis
was that the effects of directly blocking cell cycle would be less
damaging to the intestinal mucosa. Therefore, we directly compared
the intestinal mucosa of mice with CDC25 inactivation to mice
treated with the topoisomerase I inhibitor irinotecan, which induces
DNA damage thereby leading to cell cycle arrest [19]. Irinotecan
was chosen for this comparison as it is clinically effective against
several human cancers, most notably colorectal cancer [20,21].
However, mucositis is a frequent side effect of this drug [22].
A profound loss of proliferation was observed in the small
intestines of irinotecan-treated mice (Fig. 10A). The intestinal
mucosa in irinotecan-treated mice showed multiple features of
damage that were quite distinct from the mucosa of TKO mice:
i) loss of crypts (Fig. 10B), ii) increased apoptosis in the crypts
(Fig. 10 (D,E,F)), iii) lack of premature enterocytic differentiation
in the crypts (Fig. 10G), iv) loss of villus goblet cells (Fig. 10H),
and v) increase in acute inflammatory cells (Fig. 10I). Taken
together these findings demonstrate that directly blocking the
cell division through CDC25 loss is less damaging to the
intestinal mucosa than is blocking cell division by inducing DNA
damage with chemotherapy. Note that inflammation was not
observed in TKO mice where CDC25 loss theoretically occurs in
all cells and tissues of the mouse (including inflammatory cells)
or in vTKO mice where CDC25 loss is restricted to intestinal
epithelium (Fig. 10I and data not shown). Thus, failure to
observe inflammation in TKO mice cannot be attributed to
an intrinsic proliferative defect in the inflammatory cells
themselves.
Discussion
Here we describe a genetic model that enables the cell division
cycle to be acutely halted in the intestinal epithelium of adult mice.
This was accomplished by the targeted disruption of the CDC25
family of protein phosphatases using vil-Cre-ER
T2 mice, which
facilitate inducible disruption of the Cdc25s in epithelial cells but
not mesenchymal cells or other cells comprising the stem cell
niche. Current approaches to induce cell cycle arrest in the
intestine include radiation, chemotherapy or dextran sodium
sulfate-treatment. These treatments are suboptimal due to the
additional deleterious effects that they impose on the intestinal
epithelium such as DNA damage and inflammation.
The response of the small intestine to the loss of epithelial cell
proliferation is markedly distinct depending on how cell division is
blocked. Chemotherapy and radiation indirectly inhibit cell
division by inducing DNA damage. In contrast, blocking Cdc25
function inhibits cell division directly by preventing activation of
the cell cycle engine. In the latter case, Wnt-signaling was
enhanced, apoptosis was not induced and both crypt number and
structure were maintained. Importantly, the inflammatory re-
sponse was significantly milder in this model. This is in stark
contrast to irinotecan treatment, which failed to induce Wnt-
Figure 5. Significant shortening of large intestine of vABKO and vTKO mice. Mice were injected with tamoxifen for five consecutive days and
then sacrificed 3 days after the final injection. Large intestines were isolated and length determinations were made. Large intestine lengths were
normalized to body weights, which were determined prior to the first tamoxifen-injection. Data is presented as mean +/2 SEM. Asterisks indicate
significantly different after tamoxifen injection as determined by a Student’s t-test. P-values are 0.059 (WT), 0.32 (vil-Cre-ER
T2), 0.020 (vAKO), 0.27
(vBKO), 0.0009 (vABKO), 0.12 (vACKO) and 0.003 (vTKO). Large intestinal lengths of vABKO, vACKO and vTKO mice were significantly different from WT
mice injected with tamoxifen as determined by a Student’s t-test. P-values are 0.94 (vil-Cre-ER
T2), 0.82 (vAKO), 0.30 (vBKO), 0.00034 (vABKO), 0.041
(vACKO) and 0.0077 (vTKO).
doi:10.1371/journal.pone.0015561.g005
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the severe crypt loss in this model. Furthermore, goblet cells were
lost in irinotecan-treated mice and a robust inflammatory response
was observed in the intestines of these animals. Another important
conclusion that can be drawn from these studies is that the lack of
inflammation observed in the small intestines of the ROSA26-cre
model (TKO mice) is not a consequence of functional impairment
of inflammatory cells due to CDC25 loss. If this were the case,
neutrophil infiltration should have been observed in the intestines
of vTKO mice where CDC25 loss was restricted to intestinal
epithelial cells (Fig. 10I and data not shown for vTKO). These
results indicate that the inflammation observed in the small
intestines of irinotecan-treated mice is a response to the DNA
damage induced by topoisomerase I inhibition.
Despite the development of molecularly targeted therapies,
radiation and cytotoxic chemotherapies remain mainstays of
cancer treatment. These treatments induce cell cycle arrest and
apoptosis of crypt epithelial cells leading to an inflammatory
response and in some cases debilitating mucositis in treated
patients. The development of novel therapeutic strategies capable
of inducing cell cycle arrest in the absence of the accompanying
dose-limiting toxicities associated with radiation and chemother-
apy would be great advance in cancer treatment. Efforts are
currently underway to develop Cdc25 inhibitors for cancer
treatment. The cytotoxicity of Cdc25 inhibition needs to be
assessed before such inhibitors can proceed to the clinic. The
targeted gene knockout studies reported here support the
conclusion that the development of therapeutics that impair cell
division by inhibiting, but not fully blocking, key regulators of the
cell cycle machinery (CDC25s) may have fewer deleterious GI
side-effects than chemotherapeutic agents that block cell division
by inducing DNA damage. Interestingly CDC25A and CDC25B
but not CDC25C are overproduced in several human tumors and
their overproduction correlates with poor clinical outcome [23].
Thus, CDC25-inhibitors targeting either CDC25A or Cdc25B
may have the useful property of exhibiting anti-tumor activity in
those cancers overproducing these phosphatases without inducing
the deleterious GI side effects associated with radiation and
chemotherapy.
The phenotypes arising in mice deleted for all three family
members in intestinal epithelium (vTKO mice) were consistent with
those observed in mice globally deleted for all three family
members (TKO mice) using Rosa-CreER
T mice [7]. The phenotype
observed in both cases was a profound cessation of proliferation of
small intestinal epithelial stem cells and progenitors accompanied
by hypoplastic crypts, shortened villi, an overall shortening of
small intestinal length and ultimately animal death. These results
allow us to conclude that mice globally deleted for the Cdc25s die
due to the loss of proliferation of intestinal epithelial cells and that
the loss of Cdc25s in other cell types and tissues of the intestine
including mesenchyme, muscle, blood and endothelium does not
contribute significantly to the death observed in TKO mice [7].
Furthermore, this data demonstrates that enhanced Wnt signaling
observed in these mice is a compensatory response to the loss of
intestinal epithelial cell proliferation. Finally, this study demon-
strates that loss of only two family members (Cdc25A and Cdc25B)i s
sufficient to block proliferation of intestinal epithelial cells. Loss of
Cdc25C alone or in combination with loss of either Cdc25A or
Cdc25B had no effect on intestinal homeostasis or animal viability,
even though Cdc25C expression is enriched in small intestinal
crypts [7]. Thus, CDC25A and CDC25B drive proliferation of
intestinal stem and progenitor cells and loss of one can be
compensated for by the other.
How then does CDC25C contribute to the cell division cycle?
Targeted disruption of Cdc25C in mice has failed to reveal unique
or compensatory functions for this family member under steady-
state conditions. Furthermore, livers from Cdc25C knock-out mice
regenerate in a manner that is indistinguishable from livers of
control mice after a partial hepatectomy (data not shown). Like
CDC25A and CDC25B, CDC25C is regulated by protein-protein
interactions, intracellular shuttling, proteolysis and reversible
phosphorylation [24]. CDC25C has the lowest intrinsic phospha-
tase activity of the family but is potently activated during mitosis
by phosphorylation. Data amassed over the past 20 years support
a mitotic function for CDC25C although one study demonstrated
Figure 6. Response of crypt epithelial cells to loss of CDC25s.
(A) Mice were treated with tamoxifen for five consecutive days and
sacrificed 3 days after the final injection. Small intestines were isolated
and fixed. 5 mm tissue sections were prepared and stained with
Hematoxylin and Eosin. Arrow heads indicate Paneth cells. Scale bar:
0.5 mm. (B) Crypts within the proximal portion of the small intestine of
tamoxifen treated mice were examined for epithelial cells and Paneth
cells. Areas containing Brunner’s gland were excluded from analysis.
Twentycrypts werecountedpermouseandthreemiceofeachgenotype
wereevaluated.Similarpatternswereobservedinmidanddistalportions
of the small intestine (data not shown). Data is presented as mean +/2
SEM. Asterisk (*) indicates significantly different from WT mice as
determined by a Student’s t-test (total epithelial cells). *, P,0.05;
**, P,0.01; ***, P,0.001. Actual P-values are 0.41 (vil-Cre-ER
T2), 0.21
(vAKO), 0.23 (vBKO), 0.002 (vABKO), 0.15 (ACKO) and 0.0007 (vTKO). vBKO
mice have slightly more mature Paneth cells per crypt compared to WT
mice as determined by a Student’s t-test. P-values are 0.52 (vil-Cre-ER
T2),
0.77 (vAKO), 0.044 (vBKO), 0.28 (vABKO), 0.076 (ACKO) and 0.098 (vTKO).
doi:10.1371/journal.pone.0015561.g006
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15561Figure 7. Proliferation and apoptosis in crypts of Cdc25-disrupted mice. (A) Mice were injected with tamoxifen for five consecutive days and
then sacrificed 3 days after the final injection. One hour prior to sacrifice, mice were injected with BrdU. Intestines were isolated, and sections were
stained with BrdU antibody (brown) and counterstained with hematoxylin (blue). Scale bar: 20 mm. (B) Mice were injected with tamoxifen for five
consecutive days and were sacrificed 3 days after last tamoxifen injection. Intestines were isolated and sections were stained for cleaved caspase-3. 3,
39-diaminobenzidine (DAB, brown) was used as a substrate, and sections were counter-stained with hematoxylin. Arrows indicate cells at the tip of
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e15561that cells deficient in CDC25C arrest at the G1/S-border [25].
Perhaps CDC25C provides a non-essential feed-forward function
that serves to accelerate progression from prophase into
metaphase and that the effects of its loss cannot be detected
within the context of a whole organism.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Washington University (Animal Welfare Assur-
ance & Accreditation Number: A33381-01).
Mice
Generation of mice globally deleted for all three Cdc25s (TKO)
and methods used to generate and validate Cdc25B conditional
mice as well as methods used for Quantitative RT-PCR; Southern
blotting; histology; Transmission Electron Microscopy; immuno-
histochemistry; and measurements of GI tract, crypt and villi can
be found in Supplemental Material and in Lee et al. [7]. Mice
disrupted for Cdc25A [7], Cdc25B [26]; Cdc25C [27] or doubly
deleted for Cdc25B and Cdc25C [28] have been described. All mice
were of the strain background C57Bl/6;129X1SvJ. Recombinant
DNA research followed the NIH guidelines for research involving
recombinant DNA molecules.
Construction of the Cdc25B targeting vector
A 4 kb Bgl II genomic DNA fragment containing exons 1 and 2
of mouse Cdc25B was inserted into the Bam HI site of pBluescript
SK(+) (Stratagene) to generate pBSK-m25B/B4. Next, an Nhe I
genomic fragment of Cdc25B containing 7 kb of sequence
upstream of exon 1 was inserted into the Nhe I/Xba I site of
pBSK-m25B/B4 to generate pBSK-25B/BN. The 59 homology
arm containing exon 1 as well as sequences 59 and 39 of exon 1 was
isolated as a 3.3 kb fragment by digestion of pBSK-25B/BN with
Avr II. PCR was employed to amplify DNA encoding Cdc25B
from mouse 129/SvJ genomic DNA. The first PCR reaction
utilized primers 59-CTAGTCCTAGGATCACCTCTCCGT-39
and 59-GCTGACCACTGACCACAAGG-39 to amplify 6.9 kb of
Cdc25B genomic DNA beginning within intron 1 and extending
into intron 14. The second PCR reaction utilized primers 59-
CCACCCTAGGCTATCTTTGC-39 and 59-CCTAGGAAAT-
GAGACTCATAC-39 to amplify 4.5 kb of Cdc25B genomic DNA
beginning within intron 14 and extending to noncoding sequences
downstream of exon 16. PCR products were inserted into the
Topo TA vector (Invitrogen). p1339 (Genbank Accession #
AF335419) was used to assemble the targeting vector. p1339
contains a PGK-NEO cassette (phosphoglycerate kinase promoter
driving expression of neomycin phosphotransferase) flanked by 2
loxP sites. p1339 was modified by placing an additional loxP site in
Bam HI/Sac I digested p1339 to create p1339(3loxP). The 3.3kb
59 homologous arm was isolated as an Avr II fragment and cloned
into Eco RV digested p1339(3loxP). The 6.9 Kb fragment was
isolated as an Spe I/Eco RV fragment and inserted into Bam HI
digested p1339(3loxP). The 4.5kb 39 homologous arm was isolated
as an Avr II fragment and cloned into Sal I digested p1339(3loxP).
Generation of mice harboring the Cdc25B mutation
SCC10 ES cells (Siteman Cancer Center at Washington
University School of Medicine) were electroporated with
linearized targeting vector and selected with Geneticin (G418;
Invitrogen) using established protocols developed in the Siteman
Cancer Center Murine Embryonic Stem Cell Core (available
online http://escore.im.wustl.edu). A total of 142 G418-resistant
ES cell clones were analyzed for homologous recombination.
Genomic DNA was digested with Hind III and Bam HI followed
by Southern blotting with the 59 and 39 probes, respectively
(shown in Fig. 1A). Four clones were found to be positive by
Southern blotting. ES cell clones containing the recombinant allele
were expanded and transiently transfected with a plasmid
encoding Cre recombinase under the control of the CMV
promoter to remove the pGK-NEO cassette. To isolate ES cell
clones containing a Cdc25B floxed allele and lacking the pGK-
NEO cassette, genomic DNA was digested with Kpn I and
Southern blotting was performed with the internal probe shown in
Fig.1A. ES cell clones that were identified to have a floxed allele
were karyotyped and microinjected into C57BL/6 blastocysts,
which were subsequently implanted into the uteri of pseudopreg-
nant C57BL/6 X C3HF1 foster mothers. Male chimeras selected
by percentage of agouti color were mated to C57BL/6 females.
Germ line transmission was determined by agouti coat color. F1
animals were tested for the targeted Cdc25B allele by South-
ern blotting and PCR analysis of tail DNA. PCR analysis
was performed with two primers (59-TGGTCCAGCTGCAC-
TAGAAAG-39 and 59-CTTGAGCTTTTGGAGGCTCAC-39).
The sizes of WT and floxed alleles were 383 bp and 433 bp,
respectively.
Quantitative RT-PCR (qRT-PCR)
To determine the efficiency of Cre-mediated recombination at
Cdc25B locus, total RNA was isolated from the jejunums of
tamoxifen-injected animals using Trizol (Invitrogen) and RNeasy
(Qiagen). The RNA was reverse-transcribed using Superscript III
and random primers (Invitrogen). cDNA from the small intestine
of wild type mice was also amplified as a control. cDNA was
mixed with Brilliant II SYBR Green QPCR master mix
(Stratagene) along with the Cdc25B specific primer set (Forward:
59-TCCAGGGAGAGAAGGTGTCT-39,R e v e r s e :5 9-TGTCC-
ACAAATCCGTCATCT-39). Each PCR reaction was per-
formed in duplicate using an MX3005P thermocycler (Strata-
gene). For normalization, cDNA encoding 18s rRNA was
amplified with the primer set (Forward: 59-CATTCGAACG-
TCTGCCCTATC-39, Reverse: 59-CCTGCTGCCTTCCTTG-
villi, which stain positive for cleaved caspase-3. Scale bar: 0.1 mm. (C–D) Crypts within the proximal portion of the small intestine of tamoxifen
treated mice were examined for mitotic cells (presence of mitotic figures) (C) and apoptotic cells (presence of fragmented nuclei) (D). Areas
containing Brunner’s gland were excluded from analysis. Twenty crypts were counted per mouse and three mice of each genotype were evaluated.
Similar patterns were observed in mid and distal portions of the small intestine (data not shown). Data is presented as mean +/2 SEM. Asterisks in
panel C indicate significantly different from WT mice as determined by a Student’s t-test (M-phase cells). *, P,0.05; **, P,0.01; ***, P,0.001. Actual P-
values are 0.22 (vil-Cre-ER
T2), 0.045 (vAKO), 0.16 (vBKO), 0.00056 (vABKO), 0.17 (ACKO) and 0.00055 (vTKO). Asterisks in panel D indicate significantly
different number of apoptotic cells from WT mice as determined by a Student’s t-test. P-values are 0.48 (vAKO), 0.33 (vBKO), 0.0011 (vABKO), 0.064
(ACKO) and 0.0010 (vTKO). (E) Mice were injected with tamoxifen as described in A and small intestines were isolated, sectioned and stained for
inactive Cdk1 (phosphorylated on Tyr-15, brown) and counterstained with hematoxylin (blue). Arrows indicate epithelial cells positively stained with
the phospho-Tyr 15 CDK1 antibody. Scale bar: 20 mm.
doi:10.1371/journal.pone.0015561.g007
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template.
Genotyping by Southern blot analysis and PCR
Mice were euthanized 6 or 7 days post the first tamoxifen-
injection, and organs were isolated and lysed overnight in RNE
buffer (100 mM NaCl, 10 mM Tris pH 8.0, 25 mM EDTA
pH 8.0, 0.5% SDS and 0.1 mg/ml Proteinase K). Genomic DNA
was isolated by phenol/chloroform extraction and ethanol
precipitation. DNA was digested with Bst XI, separated on an
agarose gel and transferred to a nylon membrane. The primers
used to make the probes for Southern blotting (Fig. 1A–D) were as
follows 59 Probe: Forward: 59GTTGTG AGCTGCCATGTG-
GAT and Reverse: 59TGCAATCCTACCTTTGTGACG; Inter-
nal probe: Forward 59CGAGTGTGCTCTATGCGACTT and
Reverse 59GTCTTCTCT GGTTTGACTGGT and 39 Probe:
Forward 59GTAGATAGAACAATG ATCGTCG and Reverse
59CTTGAGCTTTTGGAGGCTCAC. Primers used for PCR
analysis (Fig. 1E) include Forward: 59TGGTCCAGCTGCAC-
TAGAAAG and Reverse: 59CTTGAGCTTTTGGAGGCT-
CAC.
vil-Cre-ER
T2 mice and tamoxifen administration
Mouse lines were maintained in pathogen-free conditions in the
animal facility of Washington University School of Medicine. The
Animal Studies Committee at Washington University approved all
animal procedures. vil-Cre-ER
T2 mice have been described [9].
Tamoxifen (Sigma Chemical Co.) was dissolved in sunflower seed
oil at a concentration of 10 mg/ml by sonication. Mice were
injected IP at 4 mg per 25 g body weight once per day for five
Figure 8. Enhanced Wnt-signaling and differentiation of CBC
cells in vABKO and vTKO mice. (A) Tissue sections of small intestines
prepared from Vil-Cre-ER
T2 (left panel), vABKO (middle panel) and vTKO
(right panel) mice were stained with antibodies specific for beta-catenin
(green). Nuclei were stained with hematoxylin (blue). Green hatched
lines outline nuclei. Scale bar: 20 mm. (B) Quantitation of nuclear beta-
catenin staining is shown in A. Data is presented as mean +/2 SEM.
Asterisks in panel B indicate significantly different from vil-Cre-ER
T2 mice
as determined by a Student’s t-test. (C) Intestinal sections were stained
with Periodic Acid Schiff/alcian blue to label Paneth cells and goblet
cells from Vil-Cre-ER
T2 (left panel), vABKO (middle panel) and vTKO (right
panel) mice. Insets are magnifications of boxed regions shown in
middle and right panel. Asterisks in left panel indicate CBC cells.
Asterisks in middle and right panels indicate immature Paneth cells.
Arrows in middle and right panel indicate small granules of immature
Paneth cells. Scale bar: 10 mm.
doi:10.1371/journal.pone.0015561.g008
Figure 9. Differentiation of CBC cells into immature Paneth
Cells in Cdc25-disrupted mice. Small intestines were dissected and
processed for Transmission Electron Microscopy. EM sections of crypts
from vil-Cre-ER
T2 (A), vABKO (B, C) and vTKO (D, E) mice. Insets in panels
B and D are shown at higher magnification in panels C and E,
respectively. The red-hatched lines in panel A demark two CBC cells
separated by a mature Paneth cell. Blue-hatched lines in panels B-D
outline borders of immature Paneth cells arising from premature
differentiation of CBC cells. Note that differentiating CBC cells also
undergo hypertrophy. Scale bar: 10 mm (A, B, D), 5 mm (C, E).
doi:10.1371/journal.pone.0015561.g009
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e15561Figure 10. Response of small intestinal epithelial cells to irinotecan. (A) Significant decrease in the number of BrdU postive cells in the small
intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7.
One hour prior to sacrifice, mice were injected with BrdU. Intestines were isolated and sections were stained with an antibody specific for BrdU.
Dotted lines demark crypt margins. Red: BrdU, Blue: nuclei (DAPI). Scale bar: 10 mm. (B, C) Significant loss of crypts in the small intestines of
irinotecan-treated mice. Intestines were isolated from irinotecan-treated mice (B) and TKO mice (C), and sections were stained with H & E. Arrows in
(B) indicate remaining crypts. Scale bar: 50 mm. (D–F) Irinotecan induces significant apoptosis in the crypts of treated mice at early time points after
irinotecan-treatment. (D) Intestinal sections were prepared after two irinotecan administrations and stained with H & E. Arrows depict apoptotic cells.
Scale bar: 10 mm. (E) Intestinal sections from WT mice treated with PBS (cont)) and irinotecan (CPT) were stained by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay. Green: TUNEL, Blue: nuclei (DAPI). Scale bar: 100 mm. (F) Intestinal sections from WT mice treated
with PBS (left) and irinotecan (right) were stained for cleaved caspase-3. DAB (3, 39-diaminobenzidine) was used as a substrate (brown) and sections
were counter-stained with hematoxylin (blue). Scale bar: 50 mm. (G) Differentiation along the enterocyte lineage is not affected in irinotecan-treated
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sacrificed on day 8 or earlier if they exhibited loss of 20% of
original body weight or if they were unable to access food or water.
Mice ranged in age from 2 to 3 months at the time of injection.
X-gal staining
X-gal staining was performed as described by Ahn et al. [29].
Intestines were embedded in Optimal Cutting Temperature
Medium (Tissue-Tek). Six mm sections were prepared and fixed
for 2 min in 1% formaldehyde, 0.2% glutaraldehyde, 0.02% NP-
40, 1 mM NaCl and then incubated in X-gal solution (1 part X-
gal dissolved at 40 mg/ml in dimethyl formamide in 40 parts
dilution buffer) at 37uC overnight. Dilution buffer consisted of PBS
containing 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide.
Histology
Mice were euthanized in a CO2 chamber. Brain, heart, lung,
liver, spleen, kidney and small and large intestines were isolated,
washed in phosphate-buffered saline (PBS), fixed in 10% neutrally
buffered formalin overnight and embedded in paraffin blocks.
5 mm sections were prepared and stained with H&E or Periodic
Acid Schiff (PAS)/alcian blue (AB). A veterinarian in the Division
of Comparative Medicine at Washington University in St Louis
examined all tissue sections.
GI tract, crypt and villi measurements
Stomachs as well as small and large intestines, isolated from
euthanized mice, were cut open along the cephalocaudal axis,
pinned down on a solid plate and fixed overnight with 10%
neutrally buffered formalin. Small and large intestines were
measured along their entire length and normalized with initial
body weights. Villi at the most proximal end of the small intestine
were used for length measurements. Cross sections of duodenum
were photographed under a dissection microscope and the actual
length of villi was calculated by using a scale bar taken in the same
picture. 30 villi were measured per mouse.
Immunohistochemistry
Mouse tissues were fixed in 10% neutrally buffered formalin
overnight. Tissue sections were deparaffinized in xylene, rehy-
drated in a series of alcohols and PBS. Endogenous peroxidase
activity was removed by incubating the sections in 3% hydrogen
peroxide in methanol for 10 min. Antigen retrieval techniques
were performed by boiling the sections in 10 mM sodium citrate
(pH 6.0) for 20 min. Sections were blocked with 3% bovine serum
albumin, 0.1% Triton X-100 in PBS and incubated at room
temperature for 1 h with beta-catenin antibody (BD Transduction
lab, 1:100), cleaved caspase-3 antibody (Cell Signaling, 1:100) and
phospho-Tyr-15 CDK1 antibody (Santa Cruz, 1:100). MOM kit
(BMK-2202, Vector laboratories) was used to block nonspecific
binding of secondary antibodies and 3.39-diaminobenzidine (DAB)
was used as a chromogenic substrate. Hematoxylin was used to
counter stain. For BrdU single staining, BrdU (Amersham) was IP
injected according to the manufacturer’s recommendations (2 ml
per 100 g body weight). One hour later, mice were euthanized and
their intestinal tracts were dissected and processed as described
above. BrdU staining was performed with a BrdU staining kit
(Zymed) according to the manufacturer’s instructions. Only intact
well-oriented crypts located half-way between the proximal and
distal ends of 2 cm small intestinal sections containing Paneth cells
at their base and an intact intestinal lumen composed of a single
layer of cells were examined for the presence of nuclear b-catenin.
TUNEL staining
TUNEL staining was performed according to the recommen-
dations of the manufacturer (Roche) using the In Situ Cell Death
Detection Fluorescein kit. Intestinal sections were fixed, depar-
affinized and subjected to hydrogen peroxide treatment. Sections
were treated with 20 mg/ml proteinase K in 10 mM Tris pH 7.4
for 15 min at 37uC. Sections were then treated with TUNEL
reaction mix for 1 h at 37uC. Sections were counterstained with
DAPI (nuclei counter stain) using the Prolong Gold mounting
media (Invitrogen).
Transmission Electron Microscopy
Intestines were dissected and fixed in 2% paraformaldehyde/
2.5% glutaraldehyde (Polysciences Inc., Warrington, PA) in
100 mM phosphate buffer, pH 7.2 for 1 h at room temperature.
Samples were washed in phosphate buffer and post-fixed in 1%
osmium tetroxide (Polysciences Inc.) for 1 h. Samples were rinsed
extensively in dH20 prior to en bloc staining with 1% aqueous
uranyl acetate (Ted Pella Inc., Redding, CA) for 1 h. Following
several rinses in dH2O, samples were dehydrated in a graded series
of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.).
Sections of 200 nm were cut with a Leica Ultracut UCT
ultramicrotome (Leica Microsystems Inc., Bannockburn, IL) and
stained with methylene blue to determine appropriate orientation
of the tissue. Sections of 95 nm were then obtained, stained with
uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX
transmission electron microscope (JEOL USA Inc., Peabody,
MA).
Irinotecan treatment
Irinotecan hydrochloride (CPT-11) was obtained as a 20 mg/ml
stock. Prior to administration it was diluted in 0.9% phosphate
buffered saline and the mice were injected with either 100 mg/kg
or 150 mg/kg intraperitoneally. To analyze effects of irinotecan
on intestinal cells at earlier time points, mice were injected with a
100 mg/kg dose at day 1 and day 2 and sacrificed 6 h thereafter.
For prolonged exposure studies and to obtain a maximal inhibition
of cell proliferation, mice were injected with a dose of 150 mg/kg
from day 1 through 6 and sacrificed 6 h following the last dose.
One hour prior to sacrifice, mice were also injected with BrdU.
Control mice received an equal volume of 0.9% phosphate
buffered saline.
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